The growing interest in psychedelics is reflected in drug development pipelines, which have seen an influx of psychedelic and hallucinogenic drugs. It is a promising sign that perceptions of the value of these drugs to have a meaningful impact on patient quality of life are changing, but many barriers are still likely to be faced in translating this into patient access to innovative new therapies. Nancy Cross, Senior Analyst at Lightning Health, reviews the current pipeline for psychedelic drugs in development for psychiatric, cognitive and mood disorders.